AKBA
Akebia Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.01 / 10
Netural
Analyst sentiment is neutral with two active analysts; one rates Buy and the other Strong Buy, yet historical win rates are low (0-50%). Money flow is positive (7.8/10), with overall inflow ratio at 0.4896, but block and medium-term trends are negative. This mix of bullish flow and lukewarm analyst support keeps the outlook balanced.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-06
InstitutionPiper Sandler
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of AKBA?
- AKBA holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.01/10 (Netural).
